We demonstrate that the prognostic power of analysing the presurgical CAPRA score together with the prostate cancer biomarker PDE4D7 (CAPRA and PDE4D7) can be significantly improved by adding in analyses of transcript level scores for long PDE4D isoforms PDE4D5 and PDE4D9, providing a novel risk model (CAPRA and PDE4D5/7/9). This evidence concerns the gene PDE4D and Familial prostate cancer.